It would send us above .30 cents for sure. Then, as LymPro revenues start coming in and growing it will consistently lift our pps. I think LymPro will be our primary growth engine for the next three years.
MANF indications will contribute to our pps over the next three years, but it is difficult to quantify since Retinitis is still 4 years away from commercialization. Nevertheless, RP and Wolframs (Diabetes), TBI, Hearing, PD, etc will all contribute as they progress.
Two other things in our pipeline that could add significant value in the next year or so are:
1) Eltoprazine: Positive results on its phase 2b clinical trial will probably get released near the end of 2015. That could be nice!
2) Phenoguard: John said he'd begin working on this right away, so we might find a partner on this toward the end of 2014 or in 2015.
And, there might be some things brewing with our management team that we know nothing about. For instance: Dr. Adam Simons owns a company that has a scanner they are developing that is a diagnostic tool for Alzheimers and TBI. I'm wondering if AMBS at some point might use his scanner in tandem with our LymPro blood test to further separate us from other blood tests?
News 
Market Data 
Discover 
AI
